Search Results - "Elke Schaeffeler"

Refine Results
  1. 1

    Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature by Wolking, Stefan, Schaeffeler, Elke, Lerche, Holger, Schwab, Matthias, Nies, Anne T.

    Published in Clinical pharmacokinetics (01-07-2015)
    “…ATP-binding cassette transporter B1 (ABCB1; P-glycoprotein; multidrug resistance protein 1) is an adenosine triphosphate (ATP)-dependent efflux transporter…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Clinical and Functional Relevance of the Monocarboxylate Transporter Family in Disease Pathophysiology and Drug Therapy by Fisel, Pascale, Schaeffeler, Elke, Schwab, Matthias

    Published in Clinical and translational science (01-07-2018)
    “…The solute carrier (SLC) SLC16 gene family comprises 14 members and encodes for monocarboxylate transporters (MCTs), which mediate the absorption and…”
    Get full text
    Journal Article
  4. 4

    Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry by Schaeffeler, Elke, Jaeger, Simon U., Klumpp, Verena, Yang, Jun J., Igel, Svitlana, Hinze, Laura, Stanulla, Martin, Schwab, Matthias

    Published in Genetics in medicine (01-09-2019)
    “…Severe hematotoxicity in patients with thiopurine therapy has been associated with genetic polymorphisms in the thiopurine S-methyltransferase (TPMT). While…”
    Get full text
    Journal Article
  5. 5

    Mechanisms and assessment of statin‐related muscular adverse effects by Moßhammer, Dirk, Schaeffeler, Elke, Schwab, Matthias, Mörike, Klaus

    Published in British journal of clinical pharmacology (01-09-2014)
    “…Statin‐associated muscular adverse effects cover a wide range of symptoms, including asymptomatic increase of creatine kinase serum activity and…”
    Get full text
    Journal Article
  6. 6

    Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors by Neul, Claudia, Schaeffeler, Elke, Sparreboom, Alex, Laufer, Stefan, Schwab, Matthias, Nies, Anne T

    “…Small-molecule inhibitors of tyrosine kinases (TKIs) are the mainstay of treatment for many malignancies and represent novel treatment options for other…”
    Get full text
    Journal Article
  7. 7

    Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects by Emami Riedmaier, Arian, Fisel, Pascale, Nies, Anne T, Schaeffeler, Elke, Schwab, Matthias

    “…Metformin is a biguanide derivative used in the treatment of type II diabetes (T2D) and one of the world's most widely prescribed drugs. Owing to its safety…”
    Get full text
    Journal Article
  8. 8

    Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver by Nies, Anne T., Koepsell, Hermann, Winter, Stefan, Burk, Oliver, Klein, Kathrin, Kerb, Reinhold, Zanger, Ulrich M., Keppler, Dietrich, Schwab, Matthias, Schaeffeler, Elke

    Published in Hepatology (Baltimore, Md.) (01-10-2009)
    “…An important function of hepatocytes is the biotransformation and elimination of various drugs, many of which are organic cations and are taken up by organic…”
    Get full text
    Journal Article
  9. 9

    Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs) by Nies, Anne T, Hofmann, Ute, Resch, Claudia, Schaeffeler, Elke, Rius, Maria, Schwab, Matthias

    Published in PloS one (14-07-2011)
    “…Metformin, an oral insulin-sensitizing drug, is actively transported into cells by organic cation transporters (OCT) 1, 2, and 3 (encoded by SLC22A1, SLC22A2,…”
    Get full text
    Journal Article
  10. 10
  11. 11

    Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin by Hsin, Chih-hsuan, Stoffel, Marc S., Gazzaz, Malaz, Schaeffeler, Elke, Schwab, Matthias, Fuhr, Uwe, Taubert, Max

    Published in Scientific reports (27-07-2020)
    “…Effects of different genotypes on the pharmacokinetics of probe substrates may support their use as phenotyping agents for the activity of the respective…”
    Get full text
    Journal Article
  12. 12

    Selective p38α MAP kinase/MAPK14 inhibition in enzymatically modified LDL‐stimulated human monocytes: implications for atherosclerosis by Cheng, Fei, Twardowski, Laura, Fehr, Sarah, Aner, Christoph, Schaeffeler, Elke, Joos, Thomas, Knorpp, Thomas, Dorweiler, Bernhard, Laufer, Stefan, Schwab, Matthias, Torzewski, Michael

    Published in The FASEB journal (01-02-2017)
    “…ABSTRACT The first ATP‐competitive p38a MAPK/MAPK14 inhibitor with excellent in vivo efficacy and selectivity, skepinone‐L, is now available. We investigated…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Copy number variation profiling in pharmacogenes using panel-based exome resequencing and correlation to human liver expression by Tremmel, Roman, Klein, Kathrin, Battke, Florian, Fehr, Sarah, Winter, Stefan, Scheurenbrand, Tim, Schaeffeler, Elke, Biskup, Saskia, Schwab, Matthias, Zanger, Ulrich M.

    Published in Human genetics (01-02-2020)
    “…Structural variants including copy number variations (CNV) have gained widespread attention, especially in pharmacogenomics but for several genes functional…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17

    Platelet miRNAs: differential expression in coronary artery disease and associations with course of left ventricular systolic function by Goldschmied, Andreas, Drotleff, Bernhard, Winter, Stefan, Schaeffeler, Elke, Schwab, Matthias, Gawaz, Meinrad, Geisler, Tobias, Rath, Dominik

    Published in BMC cardiovascular disorders (12-07-2023)
    “…MicroRNAs are paramount in post transcriptional gene regulation. We investigated platelet miRNAs in patients with CAD and examined potential associations with…”
    Get full text
    Journal Article
  18. 18
  19. 19
  20. 20